Several other brokerages have also issued reports on LLY. Jefferies Group set a $93.00 target price on shares of Eli Lilly and and gave the company a buy rating in a research report on Monday, February 26th. Goldman Sachs lowered shares of Eli Lilly and from a buy rating to a neutral rating and lifted their target price for the company from $86.98 to $95.00 in a research report on Tuesday, January 16th. Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $85.00 target price on the stock in a research report on Tuesday, April 3rd. Argus upgraded shares of Eli Lilly and from a hold rating to a buy rating and lifted their target price for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Bank of America dropped their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a neutral rating on the stock in a research report on Thursday, February 1st. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Eli Lilly and has a consensus rating of Hold and an average target price of $92.84.
LLY opened at $76.85 on Wednesday. Eli Lilly and has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The firm has a market capitalization of $86,135.91, a price-to-earnings ratio of 17.96, a PEG ratio of 1.43 and a beta of 0.26. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares in the company, valued at approximately $12,339,974.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joshua L. Smiley sold 3,000 shares of the business’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $79.20, for a total transaction of $237,600.00. Following the completion of the transaction, the chief financial officer now owns 20,029 shares in the company, valued at $1,586,296.80. The disclosure for this sale can be found here. Insiders have sold 15,261 shares of company stock worth $1,225,085 over the last 90 days. 0.11% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of LLY. Avestar Capital LLC acquired a new position in Eli Lilly and in the 4th quarter valued at about $100,000. Gradient Investments LLC acquired a new position in Eli Lilly and in the 4th quarter valued at about $103,000. Front Row Advisors LLC acquired a new position in Eli Lilly and in the 4th quarter valued at about $137,000. Willingdon Wealth Management acquired a new position in Eli Lilly and in the 3rd quarter valued at about $138,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in Eli Lilly and in the 3rd quarter valued at about $142,000. Institutional investors own 77.63% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Eli Lilly and (LLY) Rating Reiterated by BMO Capital Markets” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3340154/eli-lilly-and-lly-rating-reiterated-by-bmo-capital-markets.html.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.